Literature DB >> 18209894

[Metabolic syndrome, its phenotypes, and insulin resistance by HOMA-IR].

Ernesto P de Oliveira1, Maria das Dores A v Lima, Mirabeau Levi A de Souza.   

Abstract

The diagnosis of the metabolic syndrome (MS) according to the National Cholesterol Education Program Adult Treatment Panel III does not reflect necessarily the presence of insulin resistance (IR), a potential therapeutical target for type 2 diabetes and cardiovascular disease prevention. Based on previous prevalence data, a cross-sectional study was conducted to determine the HOMA-IR relationship to the MS and some associated abnormalities. HOMA-IR > was higher in individuals with the MS (2.8+/-1.6 vs. 1.8+/-1.4) (p < 0.001). HOMA-IR >or= 2.5 allied good specificity and sensitivity levels for the association of MS and IR. Hyperglycemia, hypertrigliceridemia, and abdominal obesity, the MS components best related to IR, were statistically associated with HOMA-IR > 2.5, but not hypertension neither low HDL-c. The demonstration that some of MS phenotypes or associated abnormalities were more predictive for IR could point out to the possibility of the use of the index as a marker of the presence of IR associated to MS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18209894     DOI: 10.1590/s0004-27302007000900014

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  3 in total

1.  The 482Ser of PPARGC1A and 12Pro of PPARG2 Alleles Are Associated with Reduction of Metabolic Risk Factors Even Obesity in a Mexican-Mestizo Population.

Authors:  Mónica Vázquez-Del Mercado; Milton-Omar Guzmán-Ornelas; Fernanda-Isadora Corona Meraz; Clara-Patricia Ríos-Ibarra; Eduardo-Alejandro Reyes-Serratos; Jorge Castro-Albarran; Sandra-Luz Ruíz-Quezada; Rosa-Elena Navarro-Hernández
Journal:  Biomed Res Int       Date:  2015-06-22       Impact factor: 3.411

2.  Sleepiness, inflammation and oxidative stress markers in middle-aged males with obstructive sleep apnea without metabolic syndrome: a cross-sectional study.

Authors:  Daniela Kuguimoto Andaku; Vânia D'Almeida; Gláucia Carneiro; Sônia Hix; Sergio Tufik; Sônia Maria Togeiro
Journal:  Respir Res       Date:  2015-01-14

3.  Tamarind Trypsin Inhibitor in Chitosan-Whey Protein Nanoparticles Reduces Fasting Blood Glucose Levels without Compromising Insulinemia: A Preclinical Study.

Authors:  Lídia L R Matias; Rafael O A Costa; Thaís S Passos; Jaluza L C Queiroz; Alexandre C Serquiz; Bruna L L Maciel; Pedro P A Santos; Christina S Camillo; Catarina Gonçalves; Isabel R Amado; Lorenzo Pastrana; Ana H A Morais
Journal:  Nutrients       Date:  2019-11-14       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.